



Charité Research
Organisation

HUMAN INTERVENTION STUDIES TO SUPPORT HEALTH CLAIMS



Charité Research Organisation (CRO) designs and conducts human intervention studies to help substantiate health claims, demonstrate product safety and generally support the R&D process.

CRO conducts studies in a controlled research unit with a dedicated study team. Central to our offering is a close collaboration with our parent organisation, Europe's leading university hospital: Charité - Universitätsmedizin Berlin. CRO focuses on the selection and implementation of appropriate study designs incorporating surrogate endpoints and biomarkers that are readily accepted within the scientific community. This in turn helps to ensure that the EFSA guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims is met.

Charité Research
Organisation GmbH

Charitéplatz 1
10117 Berlin, Germany

Tel. +49 (0)30 450 539 200
Fax +49 (0)30 450 539 900

enquiries@charite-research.org
www.charite-research.org

INNOVATION AND EFFECTIVENESS



CASE STUDIES

PROBIOTIC		
Study in 220 healthy volunteers to evaluate the ability of a probiotic to reduce the incidence of upper respiratory tract and gastrointestinal infections.	Enrolment completed at CRO in Berlin within 2 months.	Use of questionnaires and physicians evaluation, extensive biomarker panel to explore mode of action
OXI-INFLAMM-AGING		
Study in 30 post-menopausal women to evaluate the impact of a supplement on biomarkers of oxi-inflamm-aging.	Completed at CRO in Berlin within 3 months.	Use of questionnaires and highly sensitive biomarker panel to evaluate effect
ALLERGIC RHINITIS		
Study in 120 subjects with allergic rhinitis to evaluate potential of a product to mitigate symptoms.	Enrolment completed at CRO in Berlin within 1 month.	Symptom scores and rescue medication use evaluated, biomarker panel to explore mode of action

ABOUT US

Charité Research Organisation (CRO) supports the nutrition and consumer health care industries in addition to its core pharmaceutical and biopharmaceutical client base. With respect to the pharmaceutical industry, CRO focuses on early clinical development, helping its clients to investigate both safety and efficacy by involving patients early on and through the innovative use of diagnostics and biomarkers. This approach to helping the pharmaceutical industry gain more information from early clinical studies translates well to the ever more stringent requirements to substantiate health claims.

Based in Berlin, CRO was founded in collaboration with Charité - Universitätsmedizin Berlin, one of Europe's largest university hospitals. This allows CRO to benefit from leading clinical and methodological expertise, as well as access to cutting edge diagnostic technologies and biomarker research.

CRO operates its own dedicated research unit with a current capacity of 30 beds for in-patient studies. This is supplemented by a facility dedicated to out-patient studies and human intervention studies for the nutrition and consumer health care industries.

We are working in the following areas:

- > Immunology
- > Cardiovascular Health
- > Weight Management
- > Skin Health (Anti-Aging)
- > Digestive Health
- > Bone/Skeletal Health
- > Energy/Physical Performance Enhancers
- > Cognitive/Mental Performance Enhancers
- > Psychological Health